scispace - formally typeset
S

Supakarn Chamni

Researcher at Chulalongkorn University

Publications -  44
Citations -  500

Supakarn Chamni is an academic researcher from Chulalongkorn University. The author has contributed to research in topics: Chemistry & Lung cancer. The author has an hindex of 11, co-authored 32 publications receiving 331 citations. Previous affiliations of Supakarn Chamni include Texas A&M University.

Papers
More filters
Journal ArticleDOI

Potential Anti-metastasis Natural Compounds for Lung Cancer.

TL;DR: As lung cancer is the most common malignancy worldwide and high mortalities are the result of metastasis, novel information surpassing the treatment strategies and therapeutic agents focusing on cancer dissemination are of interest.
Journal ArticleDOI

Recent progress and challenges in the discovery of new neuraminidase inhibitors.

TL;DR: A potential pitfall in NA-based assays and the progress in the chemical synthesis of all patented NAIs from February 2006 to July 2012 are discussed, which suggest that the strategy of designing NAIs binding to the highly conserved region of NA can lead to inhibitors that are effective against all influenza NA subtypes.
Journal ArticleDOI

Diazo reagents with small steric footprints for simultaneous arming/SAR studies of alcohol-containing natural products via O-H insertion.

TL;DR: Novel diazo reagents for simultaneous arming and structure-activity relationship (SAR) studies of alcohol-containing natural products with a small steric footprint, namely, an α-trifluoroethyl (HTFB) substituted reagent are described.
Journal ArticleDOI

Rosmarinic Acid as a Potent Influenza Neuraminidase Inhibitor: In Vitro and In Silico Study.

TL;DR: Investigating the anti-influenza NA activity of caffeic acid and its hydroxycinnamate analogues, rosmarinic acid and salvianolic acid A, in comparison to a known NA inhibitor, oseltamivir shed light on the potentiality of ros marinic acid as a lead compound for further development of a potential influenza NA inhibitor.
Journal ArticleDOI

β-Lactam congeners of orlistat as inhibitors of fatty acid synthase

TL;DR: Beta-lactam derivatives of orlistat were prepared and their inhibitory activities toward the thioesterase domain of fatty acid synthase (FAS-TE) were evaluated using a recombinant form of the enzyme.